So it is reasonable to assume that RBS has reinforced its foundations and structure to cope with all but the most acute and extreme of financial shocks.
The work should begin with a shakeout of the FDA regulatory apparatus, an archaic structure that can no longer cope with the pace and complexity of modern bioscience.